Hanmi Science and Hanmi Pharmaceutical Receive 'AA-' Rating from NICE Investors Service... Highest in the Industry

Hanmi Pharmaceutical Upgraded by Two Notches from Previous Rating

Hanmi Science and Hanmi Pharmaceutical announced on October 13 that they have received a corporate credit rating of 'AA- (Stable)' from NICE Investors Service, one of the top three credit rating agencies in Korea.

Yonhap News Agency

Based on the interim financial statements as of the reference date in 2025, Hanmi Science received the highest rating among major holding companies in the domestic pharmaceutical industry. NICE Investors Service cited the following as the basis for its evaluation: ▲ the strong business competitiveness and financial stability of its core affiliate Hanmi Pharmaceutical ▲ stable control over key subsidiaries such as Online Pharm and JVM.

Hanmi Pharmaceutical’s rating was upgraded by two notches from its previous 'A' to 'AA-' as a result of improvements in business performance and financial structure. This is the first upgrade in two years since the regular evaluation by NICE Investors Service and Korea Investors Service in June 2023.

NICE Investors Service stated, "As the holding company of the Hanmi Pharmaceutical group, Hanmi Science maintains stable control over its major subsidiaries, and is also expected to generate stable profits from its own business operations."

Regarding Hanmi Pharmaceutical, the agency commented, "Based on the solid sales growth of its main product lines, revenue has steadily increased from 1.1 trillion won in 2020 to 1.5 trillion won in 2024. With continued investment in research and development (R&D) leading to new drug development and excellent portfolio management capabilities, the company is expected to maintain a stable business foundation in the medium term."

A Hanmi Group representative explained, "'AA-' is considered a very high grade within the domestic credit rating system, reflecting Hanmi Group’s solid financial stability and business sustainability."

The representative added, "Based on a more transparent and sound governance structure, we will focus on developing innovative new drugs and discovering future growth engines. Furthermore, we will strive for responsible and professional management so that Hanmi Group can be recognized as a trusted company by shareholders, customers, and all stakeholders across society."

This content was produced with the assistance of AI translation services.